

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**邁博藥業**  
**Mabpharm Limited**  
**迈博药业有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2181)**

**VOLUNTARY ANNOUNCEMENT**  
**BUSINESS COOPERATION AGREEMENT WITH JIANGSU SIMCERE**  
**ZAIMING IN RELATION TO CMAB009 IN CHINA**

This announcement is made by Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

**BUSINESS COOPERATION AGREEMENT WITH JIANGSU SIMCERE ZAIMING**

The board of directors of the Company (the “**Board**”) is pleased to announce that on August 18, 2023, Taizhou Mabtech Pharmaceutical Limited\* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”), an indirect wholly-owned subsidiary of the Company, entered into a business cooperation agreement (the “**Agreement**”) with Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd\*. (江蘇先聲再明醫藥有限公司) (“**Jiangsu Simcere Zaiming**”) (a wholly-owned subsidiary of Simcere Pharmaceutical Group Limited (“**Simcere**”), a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2096)), pursuant to which Taizhou Pharmaceutical granted exclusive commercial rights in respect of CMAB009 (including but not limited to sales management, marketing and promotion, formulation and adjustment of related strategies and the rights to obtain relevant benefits) in the Chinese mainland (“**Cooperation Area**”) to Jiangsu Simcere Zaiming. Taizhou Pharmaceutical will continue to possess all the rights and interests in respect of CMAB009 in the Cooperation Area other than the aforementioned commercial rights. On the basis of complying with the provisions of the Agreement, Jiangsu Simcere Zaiming shall be entitled to provide exclusive promotion services in respect of CMAB009 in the Cooperation Area.

The Company's product pipeline covers drugs in immunology, allergy, oncology, gastroenterology and other fields. The Company's sales strategy will be more focused on the sales of relevant drugs in advantageous fields, and it will actively cooperate with companies with rich experience and long-established resources to expedite the introduction of marketing resources and achieve a rapid increase in market share, so as to leverage economies of scale and scaling effect brought by cooperation. Entering into the Agreement will be conducive to enhancing the brand influence of CMAB009 and provide exponential momentum for rapid growth of sales of the Company's products.

## **ABOUT CMAB009**

CMAB009 is a recombinant anti-epidermal growth factor receptor (“**EGFR**”) chimeric monoclonal antibody for first-line treatment of metastatic colorectal cancer (“**mCRC**”) in combination with FOLFIRI. CMAB009 is prepared using a specific expression process developed by the Company, effectively avoiding glycosylation modification that may lead to hypersensitivity. The safety and efficacy of CMAB009 have been confirmed from the results of two completed clinical trials. By comparing the Company's clinical trial results to the published clinical trial results for currently marketed traditional anti-EGFR monoclonal antibody drugs, CMAB009 has a significant therapeutic effect when compared with currently marketed traditional anti-EGFR monoclonal antibody drugs for treatment of mCRC.

The drug marketing application for CMAB009 was accepted by the National Medical Products Administration of China in March 2023, and we expect that CMAB009 will be approved for marketing in the second quarter of 2024. We expect that upon commercialization, CMAB009 will be the first home-made anti-EGFR monoclonal antibody drug for treatment of mCRC launched in the Chinese market, and is expected to provide affordable biological targeted remedy with better efficacy for hundreds of thousands of Chinese patients with tumors. At the same time, CMAB009 is also expected to expand its indications to pancreatic cancer, head and neck squamous cell carcinomas, cervical squamous cell carcinoma and other cancers, as its administration together with a variety of small molecule drugs has tremendous potential for application in various other cancer types. The Company will expedite the clinical and registration work of CMAB009.

## **ABOUT SIMCERE**

Simcere is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. Simcere focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today's patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes.

## **ABOUT JIANGSU SIMCERE ZAIMING**

As a wholly-owned subsidiary of Simcere, Jiangsu Simcere Zaiming is committed to providing differentiated therapeutic drugs with better efficacy for patients diagnosed of tumor leveraging innovative approaches. Jiangsu Simcere Zaiming enjoys profound experience in clinical trials and registration of anti-tumor drugs, maintains a team of professionals engaged in academic promotion and market access in the Chinese mainland and boasts rich experience in commercialisation.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to obtain approval for, develop or ultimately market, CMAB009 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Mabpharm Limited**  
**Jiao Shuge**  
*Chairman*

Hong Kong, August 18, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.*

\* *For identification purpose only*